Your browser is no longer supported. Please, upgrade your browser.
AZN AstraZeneca PLC weekly Stock Chart
AZN [NYSE]
AstraZeneca PLC
Index- P/E42.23 EPS (ttm)0.95 Insider Own0.50% Shs Outstand2.62B Perf Week-0.22%
Market Cap105.24B Forward P/E19.79 EPS next Y2.03 Insider Trans0.00% Shs Float2.61B Perf Month-3.74%
Income2.41B PEG2.53 EPS next Q0.30 Inst Own19.20% Short Float0.45% Perf Quarter3.40%
Sales22.40B P/S4.70 EPS this Y-9.60% Inst Trans0.00% Short Ratio3.50 Perf Half Y10.55%
Book/sh4.14 P/B9.69 EPS next Y15.17% ROA3.90% Target Price45.43 Perf Year7.47%
Cash/sh1.89 P/C21.23 EPS next 5Y16.70% ROE20.30% 52W Range35.30 - 43.29 Perf YTD5.63%
Dividend1.40 P/FCF- EPS past 5Y-3.60% ROI10.90% 52W High-7.33% Beta0.51
Dividend %3.49% Quick Ratio0.60 Sales past 5Y-3.10% Gross Margin79.90% 52W Low13.65% ATR0.54
Employees64400 Current Ratio0.70 Sales Q/Q6.00% Oper. Margin16.90% RSI (14)47.09 Volatility0.95% 1.09%
OptionableYes Debt/Eq2.06 EPS Q/Q74.30% Profit Margin10.70% Rel Volume1.10 Prev Close40.73
ShortableYes LT Debt/Eq1.70 EarningsJul 25 BMO Payout146.10% Avg Volume3.39M Price40.12
Recom1.60 SMA20-2.13% SMA501.38% SMA2002.03% Volume3,708,571 Change-1.50%
Apr-02-19Downgrade UBS Neutral → Sell
Feb-05-19Initiated Exane BNP Paribas Outperform
Jan-25-19Upgrade Shore Capital Hold → Buy
Dec-11-18Resumed Jefferies Hold
Oct-09-18Initiated Guggenheim Buy
Aug-16-18Downgrade Jefferies Buy → Hold
Mar-19-18Upgrade Jefferies Hold → Buy
Feb-06-18Reiterated Leerink Partners Mkt Perform $36 → $38
Feb-05-18Reiterated Bernstein Outperform $40 → $42
Jan-18-18Reiterated Leerink Partners Mkt Perform $33 → $36
Dec-29-17Upgrade JP Morgan Neutral → Overweight
Oct-16-17Upgrade Credit Suisse Neutral → Outperform
Sep-25-17Upgrade Exane BNP Paribas Neutral → Outperform
Sep-22-17Upgrade Bernstein Mkt Perform → Outperform
Sep-14-17Downgrade Liberum Buy → Hold
Sep-06-17Upgrade Natixis Bleichroeder Neutral → Buy
Aug-09-17Upgrade Investec Hold → Buy
Jul-28-17Downgrade Morgan Stanley Overweight → Equal-Weight
May-12-17Upgrade Credit Suisse Underperform → Neutral
Apr-10-17Downgrade Jefferies Buy → Hold
Jul-19-19 09:53AM  Pharma Stock Roundup: JNJ & NVS' Q2 Earnings, Pipeline/Regulatory Updates in Focus Zacks
Jul-18-19 09:00AM  Edited Transcript of AZN.L earnings conference call or presentation 27-Jan-11 12:00pm GMT Thomson Reuters StreetEvents
Jul-17-19 11:20AM  Inovio (INO) Ends Some Early-Stage R&D Programs, Cuts Jobs Zacks
Jul-16-19 11:33PM  AstraZeneca to pay millions of pounds to former staff Financial Times
07:00PM  FOCUS-As steep patent cliff looms, Shionogi moves to develop its own U.S. sales staff Reuters
12:12PM  Philadelphia cell therapy startup adds Big Pharma veteran to its team American City Business Journals
09:36AM  Alkermes to Include Bipolar I Disorder in ALKS 3831 NDA Zacks
Jul-15-19 09:16PM  PRESS DIGEST- British Business - July 16 Reuters
05:43PM  AstraZeneca's Farxiga Gets CRL from FDA for Type I Diabetes Zacks
04:44PM  Top Stock Reports for Cisco, Home Depot & Merck Zacks
07:00AM  AI Drug Hunters Could Give Big Pharma a Run for Its Money Bloomberg
03:07AM  UPDATE 1-AstraZeneca's Farxiga fails to get U.S. approval for Type-1 diabetes Reuters
02:31AM  RPT-AstraZeneca's Farxiga fails to get FDA approval for Type-1 diabetes Reuters
Jul-14-19 12:35AM  GSK to appoint Jonathan Symonds as chairman Financial Times
Jul-12-19 11:28AM  AstraZeneca's Imfinzi Gains Orphan Drug Status for SCLC Zacks
11:10AM  Why one top exec at this $105 billion drugmaker is 'very disappointed' with Trump Yahoo Finance
10:48AM  AstraZeneca weighs in on Trump's attack on big drug Yahoo Finance Video
09:30AM  AstraZeneca Outlines Drug Pipeline, Partnerships, Pricing Impacts TheStreet.com
Jul-11-19 09:50AM  Here's how you can find the prices of some popular drugs online Yahoo Finance
05:00AM  AstraZeneca takes lessons from fast food to serve China Financial Times
Jul-09-19 09:45AM  Intra-Cellular Therapies' Candidate Fails in Phase III Study Zacks
Jul-08-19 05:05PM  AVEO Pharmaceuticals Down More Than 50% YTD: Here's Why Zacks
Jul-05-19 09:32AM  Pharma Stock Roundup: PFE's Regulatory/Pipeline Updates, CHMP Nod for Several Drugs Zacks
Jul-03-19 01:54PM  Roche's Flu Medicine Xofluza Meets Goal in Study on Kids Zacks
Jul-02-19 02:34PM  GSK hikes price of subsidiary Tesaro's ovarian cancer drug American City Business Journals
09:01AM  AstraZeneca Gets CHMP Nod for Forxiga/Fasenra Expanded Label Zacks
Jun-30-19 03:13AM  What Did AstraZeneca PLC's (LON:AZN) CEO Take Home Last Year? Simply Wall St.
03:09AM  How Much Are AstraZeneca PLC (LON:AZN) Insiders Spending On Buying Shares? Simply Wall St.
Jun-28-19 05:08PM  AstraZeneca's Imfinzi Meets Endpoint in Lung Cancer Study Zacks
Jun-27-19 08:56AM  IMFINZI® (durvalumab) Improves Overall Survival at Interim Analysis in the Phase III CASPIAN Trial in 1st-Line Extensive-Stage Small Cell Lung Cancer Business Wire
Jun-24-19 08:33AM  Pfizer's Talzenna Gets Approval in Europe for Breast Cancer Zacks
Jun-21-19 09:07AM  Pharma Stock Roundup: PFE to Buy ARRY, RHHBY, MRK, AZN Drugs Get Regulatory Nod Zacks
06:27AM  Investors Chronicle: Telecom Plus, International Consolidated Airlines, AstraZeneca Financial Times
Jun-20-19 09:18AM  AstraZeneca's Triple-Combo COPD Inhaler Gets Japan's Nod Zacks
Jun-19-19 05:21PM  Ironwood's Linzess Lowers Abdominal Symptoms in IBS-C Patients Zacks
Jun-18-19 08:59AM  AstraZeneca/Merck's Lynparza Wins EU Nod for First-Line Use Zacks
03:05AM  AstraZeneca's Lynparza gets EU nod as first-line ovarian cancer maintenance treatment Reuters
03:02AM  UPDATE 1-AstraZeneca's Lynparza gets EU nod as first-line ovarian cancer maintenance treatment Reuters
02:35AM  AstraZeneca's Lynparza gets EU nod as first-line ovarian cancer maintenance treatment Reuters
Jun-17-19 09:51AM  AstraZeneca Gives Detailed Data From Calquence Leukemia Study Zacks
Jun-15-19 07:00AM  CALQUENCE® (acalabrutinib) Significantly Prolonged the Time Patients Lived without Disease Progression in Relapsed or Refractory Chronic Lymphocytic Leukemia Business Wire
Jun-14-19 06:00PM  Is AstraZeneca plc (AZN) A Good Stock To Buy? Insider Monkey
08:42AM  Pharma Stock Roundup: MRK Buys Small Cancer Biotech, RHHBY, MRK Drugs Get FDA Nod Zacks
07:00AM  LOKELMA Demonstrated Efficacy in Treating Hyperkalemia in Patients with End-Stage Renal Disease on Hemodialysis Business Wire
Jun-13-19 04:12PM  Amgen, Biogen, Gilead and Novo Nordisk have very high capacity for M&A, says Moodys MarketWatch
09:31AM  Keytruda & 4 Other Reasons to Invest in Merck's (MRK) Stock Zacks
Jun-10-19 09:57AM  The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AstraZeneca Zacks
08:00AM  FARXIGA Study Showed Reduced Progression of Kidney Disease or Renal Death in Patients with Type 2 Diabetes Business Wire
01:19AM  What Kind Of Shareholders Own AstraZeneca PLC (LON:AZN)? Simply Wall St.
Jun-07-19 11:53AM  New Sanofi CEO 2019: 8 Things to Know About Paul Hudson InvestorPlace
11:04AM  AstraZeneca's Calquence Meets Endpoint in 2nd CLL Study Zacks
10:21AM  Pharma Stock Roundup: ASCO Update, FDA Nod for LLY's Emgality for Cluster Headache Zacks
Jun-06-19 09:09AM  Was ASCO Quieter for Big Drug/Biotech Stocks This Year? Zacks
Jun-05-19 03:11PM  Cancer-Fighting Stocks & ETF: What You Need to Know Zacks
12:21PM  How Merck reached new ground in the fight against cancer Yahoo Finance Video
09:50AM  Ironwood Initiates Dosing in Mid-Stage Study for MD-7246 Zacks
09:09AM  Glaxo's Nucala Gets CHMP Nod for 2 Self-Administered Options Zacks
Jun-03-19 08:17PM  PRESS DIGEST- British Business - June 4 Reuters
03:14PM  AstraZeneca searches for successor to Chairman Johansson - Sky News Reuters
02:46PM  Why Cancer-Fighting Stocks & ETFs Are Soaring Zacks
02:29PM  AstraZeneca searches for successor to Chairman Johansson - Sky News Reuters
10:42AM  AstraZeneca's Imfinzi Shows Long-Term Benefits in Lung Cancer Zacks
04:11AM  Opening Quote: Kier has some nasty news for shareholders Financial Times
Jun-02-19 10:30PM  PRESS DIGEST- Financial Times - June 3 Reuters
01:10PM  Lynparza stalls pancreatic cancer in patients with BRCA mutations -study Reuters
12:09PM  Lynparza stalls pancreatic cancer in patients with BRCA mutations -study Reuters
09:00AM  IMFINZI® (Durvalumab) is the Only Immunotherapy to Demonstrate Overall Survival at Three Years in Unresectable, Stage III Non-Small Cell Lung Cancer Business Wire
12:42AM  AstraZeneca reports encouraging results for early-stage cancer treatments Financial Times
May-31-19 11:25AM  Why Inovio Pharmaceuticals Stock Is Sinking Today Motley Fool
May-29-19 03:29PM  Merck (MRK) Up This Year So Far: Will the Momentum Continue? Zacks
10:34AM  Allergan's (AGN) Vraylar Gets FDA Nod for Bipolar Depression Zacks
May-28-19 06:19PM  Inovio Pharma stock slips as AstraZeneca unit scales back agreement MarketWatch
12:29PM  Gaithersburgs Viela Bio strikes $220M deal with Chinese drug company American City Business Journals
12:50AM  Tesla, General Motors, Alibaba, and More: Why These Stocks Are in the Spotlight Insider Monkey
May-27-19 10:20AM  Novartis Gets FDA Nod for Breast Cancer Drug & Gene Therapy Zacks
May-22-19 07:00AM  Bob Harper and AstraZeneca Expand Survivors Have Heart Initiative to Empower and Unite Heart Attack Survivors Nationwide Business Wire
May-21-19 02:27AM  Despite Its High P/E Ratio, Is AstraZeneca PLC (LON:AZN) Still Undervalued? Simply Wall St.
May-20-19 12:31PM  Drugmakers lobbying spending at 10-year high as Washington targets soaring prices MarketWatch
08:00AM  FASENRA® (benralizumab) reduces oral corticosteroid use and maintains long-term efficacy and safety profile in severe eosinophilic asthma Business Wire
May-17-19 09:05AM  Rigel Initiates Enrollment in Pivotal Blood Disorder Study Zacks
May-16-19 08:00AM  AstraZeneca Continues to Redefine Cancer Treatment at The 2019 ASCO Annual Meeting Business Wire
May-15-19 09:07AM  3 Top Diabetes Stocks to Watch in May Motley Fool
May-14-19 11:51AM  AstraZeneca Needs New Breast Cancer Drug to be Blockbuster GuruFocus.com
May-11-19 02:51AM  AVEO Pharmaceuticals (AVEO) Q1 Earnings & Revenues Miss Mark Zacks
May-10-19 03:29PM  AVEO Pharmaceuticals (AVEO) Q1 Earnings & Revenues Miss Mark Zacks
10:21AM  Inovio (INO) Q1 Earnings & Revenues Fall Short of Estimates Zacks
07:34AM  Pharma Stock Roundup: AGN, NVO Report Q1 Earnings, NVS to Buy Takeda's Eye Drug Zacks
May-09-19 01:30AM  AstraZeneca Gets an $8 Billion Punishment Bloomberg
May-08-19 09:46AM  Clovis (CLVS) Q1 Earnings Top Estimates, Rubraca Sales Strong Zacks
07:00AM  AstraZeneca Teams Up with PGA Golf Champion Jason Day to Raise Awareness about the Importance of Biomarker Testing in Lung Cancer Business Wire
May-07-19 10:53AM  Guardant Health (GH) to Report Q1 Earnings: What's in Store? Zacks
May-03-19 09:00AM  Change Makers Across the Oncology Community Recognized at 2019 Cancer Community (C2) Awards Business Wire
08:36AM  Ironwood (IRWD) Q1 Earnings & Revenues Miss, Shares Fall Zacks
May-02-19 11:47AM  Edited Transcript of AZN.L earnings conference call or presentation 26-Apr-19 11:00am GMT Thomson Reuters StreetEvents
08:16AM  The Daily Biotech Pulse: FDA Nod For Sanofi's Dengue Vaccine, Veracyte Offering, Biogen Reports Positive Data Benzinga
03:05AM  AstraZeneca ties up with France's Transgene to develop viral immunotherapies Reuters
May-01-19 08:50AM  BenevolentAI starts AI collaboration with AstraZeneca to accelerate drug discovery TechCrunch
02:23AM  An Intrinsic Calculation For AstraZeneca PLC (LON:AZN) Suggests It's 46% Undervalued Simply Wall St.
Apr-30-19 01:00PM  Health Care Stocks: Buy Them While They're Down Kiplinger
11:39AM  AVEO Pharmaceuticals (AVEO) to Post Q1 Earnings: What's Up? Zacks
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. AstraZeneca PLC has a collaboration and license option agreement with Transgene SA for clinical development and commercialization of novel oncolytic immunotherapies. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ASTRAZENECA PLC10% OwnerOct 22Buy5.00600,0003,000,0003,004,554Oct 24 04:16 PM
ASTRAZENECA PLC10% OwnerSep 28Buy15.00246,6663,699,9902,164,855Oct 02 09:35 PM